16 companies join Innosuisse’s first scale-up programme - Aspivix

Scaleupgrowth-1

16 companies join Innosuisse’s first scale-up programme

January 13, 2020

Share this story:

More from our blog

Bayer (Schweiz) AG and ASPIVIX collaborate to reduce pain in Women’s Health procedures

Bayer (Schweiz) AG and ASPIVIX collaborate to reduce pain in Women’s Health procedures

ASPIVIX Receives CE Mark Approval for Carevix™

ASPIVIX Receives CE Mark Approval for Carevix™

New board members (2)

Welcoming Excellence to Aspivix’s Board: Dr. Susan Nicholson and Jessica J. Federer

X-HEALTHshow_Aspivix_cover-1

Aspivix CEO Mathieu Horras Discusses How Much IUD Insertion Can Hurt Less on X-Health.show

Removing-pain-from-just-a-Little-Pinch-Blog

Aspivix mentioned in MD+DI – “Removing the Pain from ‘Just a Little Pinch’ Gynecological Procedures”

Aspivix featured in forbes

Aspivix Featured in Forbes France Following Top 10 Placement at Inaugural MedFemTech Congress

Contraception Journal linkedin (3)

ASPIVIX Announces That Contraception, an International Reproductive Health Journal, Has Published First-In-Women Results Using Novel Cervical Stabilizer In IUD Procedures

Aspivix-FDA-510k-FDA-Approved

Aspivix receives U.S. FDA 510(k) Clearance for Carevix™, Their Novel Cervical Stabilizer

Femtech World Blog Cover

Aspivix mentioned in Femtech World about Serie A

Closed Series A+ funding round

ASPIVIX – Manufacturer of non-traumatic medical devices for gynecology – closes $5M Series A+ Funding Round and receives a large EUREKA-EUROSTARS grant co-funded by Innosuisse, the Swiss Innovation Agency.